Evidence map›Paper›PMID 40932715›Full record

ArticleJAMA network open2025

Excess HIV Infections and Costs Associated With Reductions in HIV Prevention Services in the US.

Patrick S Sullivan, Kristin M Wall, Marta Juhasz, Stephanie DuBose, Jeffrey S Crowley, Chris Breyer, Greg Millett, Kamaria Brisco, Gordon Le, Kenneth Mayer

Abstract read
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. The HIV/AIDS response as we knew it is over: Where do we go from here?Journal of the International AIDS Society · 2026
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Patrick S SullivanDepartment of Epidemiology, Emory University, Atlanta, Georgia.
Kristin M WallDepartment of Epidemiology, Emory University, Atlanta, Georgia.
Marta JuhaszSaluda Analytics, Telki, Hungary.
Stephanie DuBoseDepartment of Epidemiology, Emory University, Atlanta, Georgia.
Jeffrey S CrowleyO'Neill Institute at Georgetown Law, Washington, DC.
Chris BreyerDuke Global Health Institute, Department of Medicine, Duke University, Durham, North Carolina.
Greg MillettamfAR, Washington, DC.
Kamaria BriscoDepartment of Epidemiology, Emory University, Atlanta, Georgia.
Gordon LeDepartment of Epidemiology, Emory University, Atlanta, Georgia.
Kenneth MayerFenway Institute, Boston, Massachusetts.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Pre-exposure prophylaxis (PrEP) is a proven effective intervention to reduce the risk for HIV infection. Critically, changes in policies that lead to increased out-of-pocket PrEP costs or that decrease access to proximate PrEP locations could reduce PrEP coverage, resulting in excess HIV infections and costs. Objective: To estimate how decreases in PrEP coverage that would be likely results of federal policy changes may be associated with new HIV infections and their costs. Design, Setting, and Participants: In this economic evaluation, US population-based data sources were used to describe population-level PrEP use and new diagnoses under different hypothetical changes in PrEP coverage. Estimations of excess HIV infections under different policy changes were conducted using parameters from a previously published ecological model of the association between PrEP coverage and new HIV infections. Data on PrEP prescriptions from January 1, 2012, to December 31, 2022, and estimates from a previously reported original clinical model, which described decreases in HIV diagnoses associated with increases in population PrEP use, were analyzed. Data were analyzed from February 25 to May 23, 2025. Exposure: Change in PrEP coverage. Main Outcomes and Measures: Estimated change in new HIV infections under different assumed reductions in PrEP coverage, costs of treatment for avoidable HIV infections, and net costs of avoidable infections after accounting for costs of PrEP medications. We also estimated increases in new HIV diagnoses associated with hypothesized levels of decreasing PrEP coverage, and the costs of treating infections not averted. Results: In 2012, there were 9565 PrEP users in the US; they were predominately male (5857 [61.2%]), and 7109 (74.3%) were aged 25 to 54 years. By race and ethnicity, 1235 PrEP users (12.9%) were Hispanic, 1857 (19.4%) were non-Hispanic Black, and 5404 (56.5%) were non-Hispanic White. Based on analyses of data from a census of US PrEP users including 17 333 732 person-years of time using PrEP, an absolute 3.3% annual reduction in PrEP coverage during the next 10 years (eg, 2023 to 2033) would result in 8618 avoidable HIV infections, with lifetime medical costs of $3.6 billion (discounted) for treatment. Conclusions and Relevance: In this economic evaluation estimating effects of the possible health care policy changes on HIV transmission, findings suggest that even modest reductions in PrEP coverage would result in thousands of avoidable HIV infections and billions of dollars of increases in net health care costs.

Indexed as

Anti-HIV AgentsHealth Care CostsHIV InfectionsPre-Exposure ProphylaxisAdultFemaleHumansMaleMiddle AgedUnited StatesAnti-HIV Agents

Identifiers

PMID40932715
PMCPMC12426795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.